Importantly, a combination of highly specific and potent inhibitors of PRC2 and MEN1, which are either FDA-approved or in clinical trials to treat distinct cancer types, demonstrated remarkable efficacy in the treatment of DLBCL in xenograft study (Fig. 6). This evidence concerns the gene MEN1 and diffuse large B-cell lymphoma.